(British Approved Name, US Adopted Name, rINN)
Drug Nomenclature
International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish):
Adverse Effects and Precautions
As for alpha-glucosidase inhibitors in general (see Acarbose). Skin rash may occur. Miglitol should be used with caution in patients with renal impairment.
Interactions
As for alpha-glucosidase inhibitors in general (see Acarbose). Miglitol may reduce the bioavailability of propranolol and ranitidine.
Pharmacokinetics
Miglitol is completely absorbed at a dose of 25 mg, but only 50 to 70% is absorbed at a dose of 100 mg. It is not metabolised, and is excreted unchanged in the urine with a plasma elimination half-life of about 2 hours.
Uses and Administration
Miglitol is an alpha-glucosidase inhibitor similar in action to acarbose. It is given orally in the management of type 2 diabetes mellitus, alone or with a sulfonylurea. Usual initial doses are 25 mg three times daily with meals, increased if necessary to a maximum of 100 mg three times daily.
Proprietary Preparations
Austria: Diastabol
Czech Republic: Diastabol
France: Diastabol
Germany: Diastabol
Hungary: Diastabol
India: Diamig Mignar †
Mexico: Diastabol
Poland: Diastabol
Portugal: Diastabol Limarcan
Spain: Diastabol Plumarol
Sweden: Diastabol
Switzerland: Diastabol
USA: Glyset